As one of the national key high-tech enterprises, Shijiazhuang Yiling Pharmaceutical Co.,Ltd is founded by professor Wu Yiling, an academician of Chinese Academy of Engineering. With his leading, Yiling Pharmaceutical persists in the development strategy of scientific and technological innovation by taking science and technology as the forerunner, taking the market as the leading. Yiling Pharmaceutical founds the unique five-in-one operation mode: "Theory-Clinic-R&D-Industry-Education and the new drug research and development innovation technology system based on the theory of collateral disease. The five in one operation mode has been praised by the officer from National Ministry Of Science and Technology as "a pioneering work of the industrialization of TCM scientific and technological achievements".


Driving the industrialization of TCM by the innovation of collateral disease theory, applying modern high technology, Yiling Pharmaceutical researches and produces more than 10 national-level patent medicines which cover the major disease areas including cardiac and cerebral vascular disease, influenza and respiratory system disease, tumor and diabetes, etc. The quality management systems have passed the GMP/cGMP inspection by CFDA, USFDA and MHRA.